Recent analysis shows why GLP-1 weight-loss outcomes vary widely. Understand how sex differences, body composition, and treatment access influence results.
On September 16, 2026, The Pharmaceutical Journal published a feature examining why people experience substantially different weight-loss outcomes with GLP-1 medicines, including tirzepatide and semaglutide.
Previously, clinical expectations centered on average results from broad trials. The standard assumption was that GLP-1 medications produced a uniform weight-reduction effect across populations. This generic approach masked how widely individual responses could vary in real-world settings. It left many people frustrated when their personal outcomes did not match the typical trial averages. Medical guidance rarely accounted for how demographic factors might alter biological efficacy.
The recent analysis challenges this uniform view by detailing specific patterns in weight-loss outcomes. The evidence outlines several key variations:
The emerging evidence points toward a clear shift in how researchers approach obesity care. The medical community is transitioning from asking whether GLP-1 medicines work to asking for whom, under what conditions, and with what degree of treatment exposure they work. The Pharmaceutical Journal identifies dose escalation and prescribing access as key factors. Adherence, persistence, and affordability also influence outcomes. Comorbidities, body composition, and social circumstances further complicate the results.
Katrina Bicknell, a professor of pharmacology and pharmacy education at the University of Reading, proposed several potential contributors to these observed differences. She pointed to variations in fat mass and lean mass as central variables. She also suggested that the specific effects of oestrogen and testosterone on body tissues could influence clinical outcomes. Men typically have more muscle and less body fat than women of a similar size.
Since GLP-1 medicines appear to reduce fat mass preferentially over lean body mass, baseline body composition might directly affect results. Women with a higher proportion of fat mass might simply have more fat mass available to lose. The feature presents this idea as a hypothesis rather than a confirmed mechanism. The precise biological reasons for the sex-related pattern remain unclear.
Bicknell also addressed hormonal transitions, suggesting that declining oestrogen after menopause could influence a person's weight-loss response. She noted a different pattern among women who were taking hormone replacement therapy, but this observation remains provisional. It does not establish that menopause causes treatment failure or that hormone therapy guarantees better results. Women navigating perimenopause and hormonal shifts should discuss these nuances with a qualified clinician.
While sex and body composition are active areas of research, other demographic factors show mixed predictive value. A March 2026 review of 64 clinical trials found similar effectiveness among people younger than 65 and those aged 65 and older. The feature also reported that younger participants in the 2024 SELECT trial tended to achieve slightly greater mean weight loss with semaglutide than older participants. The differences between age groups were small.
Genetics might eventually help explain individual variation. Researchers are currently investigating possible associations between variants of the PTPRU gene and GLP-1 response. There is currently no leading gene variant capable of fully explaining why individual weight-loss outcomes differ so widely. Broad clinical monitoring remains necessary until more precise tools emerge.
Apparent differences in efficacy often stem from treatment persistence rather than biological response alone. People who stop treatment because of side effects, limited access, or high costs may be recorded as having a poor response. This distorts comparisons across different demographic groups. Fairly assessing a medicine's biological effect requires continuous and consistent use over time.
The Patientric data highlighted concerning disparities in continuation rates. One-year persistence was 20.2% among white patients but only 11.4% among Black patients. The analysis had an important limitation, as it could not track people who left the provider network. Some patients classified as stopping treatment might have simply continued their care through a different provider.
Prescribing systems and eligibility rules also affect who remains on these medications. Stringent follow-up requirements and administrative hurdles directly influence treatment continuation. These systemic barriers demonstrate that access involves much more than just the biological efficacy of the medication itself.
The variation observed between patients with and without type 2 diabetes highlights a crucial clinical distinction. In STEP 1, people without type 2 diabetes achieved a 14.9% mean weight loss after 68 weeks. Participants with type 2 diabetes in STEP 2 achieved a 9.6% reduction on the exact same dose. The article discusses several possible reasons for this significant difference in weight reduction.
Possible explanations include insulin resistance, hyperinsulinaemia, and longer-standing metabolic disease. The use of weight-promoting diabetes medicines and specific changes in the incretin system might also play a role. Even with these complexities, the feature stresses that GLP-1 medicines can still produce clinically meaningful weight loss in people with diabetes.
Amira Guirguis, chief scientist at the Royal College of Pharmacy, stressed the importance of realistic expectations. She described the sex difference in weight loss as "modest" and noted that there is "substantial overlap between individuals." Guirguis firmly advised against using population-level patterns as individual predictions. Her formulation was clear: "Sex tells us something about differences at a population level, but very little about how a particular person will respond."
When considering age as a factor, Guirguis stated that it might affect average weight loss but is "not a particularly useful predictor on its own." She also explicitly stated that current evidence does not support using race or ethnicity to predict an individual's response or determine access to treatment. Representation in clinical trials remains a critical issue for understanding these varied responses. Underrepresentation in trials reduces the statistical confidence required to identify modest differences in efficacy, safety, and tolerability.
For midlife women, this data provides valuable context for medical weight management. Percentage weight loss is only one potential outcome. Changes in blood glucose and insulin sensitivity are equally vital. Improvements in waist circumference, blood pressure, and daily mobility also matter. A woman’s own response should be assessed through clinical follow-up rather than inferred strictly from her sex alone.
Scale weight is only one measure of success. Bicknell pointed out that even modest weight loss may improve insulin sensitivity and glycaemic control in someone with type 2 diabetes. It can also significantly reduce the risk of obesity-related complications.
Protecting physical strength must remain a priority during any weight-reduction effort. Muscle mass naturally declines with age, and rapid weight loss could potentially worsen functional vulnerability. The feature does not provide sex-specific measurements of muscle loss, meaning it cannot support claims that women are protected from losing lean mass. For older or frail people, Guirguis said that maintaining muscle mass, nutrition, and physical function matters alongside weight loss.
These realities highlight the need for comprehensive strategies that support strength, body composition and metabolism. The feature frames GLP-1 treatment as one component of obesity care rather than a replacement for physical movement. Women looking for clear nutrition and weight management guidance should discuss holistic plans with their healthcare provider.
Going forward, clinical practice will likely shift from prescribing these medicines based on broad averages toward highly individualized care plans that prioritize consistent access, metabolic health monitoring, and long-term muscle preservation alongside weight management.
Navigating medical weight management requires separating genuine clinical variation from sweeping promises about how your body will respond. Refemina connects these shifts in metabolism and body composition with broader health realities, helping women navigate skin and hair changes mixed with aggressive anti-aging marketing. We translate credible evidence into clear adult guidance so you can build confidence without the wellness hype. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources